AI is accelerating drug discovery and compressing the timeline for critical intellectual property decisions. This article explores how biotech and pharmaceutical companies can build stronger patent strategies, documentation practices, and decision frameworks to protect innovation and long-term enterprise value.

As blockbuster drugs approach patent expiration, life sciences companies face significant revenue risk. Strategic patent portfolio management, validity analysis, and innovation planning can help organizations protect value and maintain competitive advantage beyond loss of exclusivity.

As innovation accelerates, life sciences companies must align patent strategy with long-term growth. This update explores how portfolio design, operational structure, and early IP decisions shape flexibility, commercialization, and long-term value.

Early-stage IP decisions in life sciences often occur under pressure but carry long-term implications for licensing, valuation, and portfolio flexibility. This article explores how early patent strategy shapes commercialization outcomes.

AI can accelerate discovery, but it can’t be the inventor. This guide explains how inventorship works in AI-assisted drug discovery, what can go wrong in real workflows, and how in-house teams can document human decision-making to protect patent enforceability and deal readiness.